Changing the face of kynurenines and neurotoxicity: Therapeutic considerations

International Journal of Molecular Sciences

Volumn 16, Issue 5, 2015, Pages 9772-9793

  Bohár, Zsuzsanna ^a   Toldi, József ^a   Fülöp, Ferenc ^b   Vécsei, László ^a,c  

^a UNIVERSITY OF SZEGED   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

^c UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Kynurenines; Neurodegeneration; Neurotoxicity

Indexed keywords

4 CHLOROKYNURENINE; ADENOSINE TRIPHOSPHATE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; ALPHA INTERFERON; BETA INTERFERON; CYTOCHROME P450; GLUTAMIC ACID; HYDROGEN PEROXIDE; HYDROXYL RADICAL; INDOLEAMINE 2, 3 DIOXYGENASE; KAINIC ACID RECEPTOR; KYNURENINE; METABOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID; NICOTINAMIDE ADENINE DINUCLEOTIDE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROGEN DIOXIDE; OXIDOPAMINE; PEROXYNITRITE; PROBENECID; PROSTAGLANDIN SYNTHASE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE; TRYPTOPHAN; TRYPTOPHAN 2, 3 DIOXYGENASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANTHINE OXIDASE; NEUROTOXIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; AUTOIMMUNITY; EXCITOTOXICITY; GLIOMA CELL; HIV ASSOCIATED DEMENTIA; HUMAN; HUNTINGTON CHOREA; IMMUNOMODULATION; INFLAMMATION; LIPID PEROXIDATION; MICROGLIA; MULTIPLE SCLEROSIS; NEUROTOXICITY; NITROSYLATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; ANIMAL; NERVE DEGENERATION; PATHOLOGY;

ANIMALS; HUMANS; KYNURENINE; NERVE DEGENERATION; NEUROTOXINS;

EID: 84929378681     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms16059772     Document Type: Review

References (143)

1. Block, M.L.; Hong, J.S. Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism. Prog. Neurobiol. 2005, 76, 77–98.
2. Gandhi, S.; Abramov, A.Y. Mechanism of oxidative stress in neurodegeneration. Oxid. Med. Cell. Longev. 2012, doi:10.1155/2012/428010.
3. Lau, A.; Tymianski, M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch. 2010, 460, 525–542.
4. Vecsei, L.; Szalardy, L.; Fulop, F.; Toldi, J. Kynurenines in the CNS: Recent advances and new questions. Nat. Rev. Drug Discov. 2013, 12, 64–82.
5. Sas, K.; Robotka, H.; Toldi, J.; Vecsei, L. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders. J. Neurol. Sci. 2007, 257, 221–239.
6. Novelli, A.; Reilly, J.A.; Lysko, P.G.; Henneberry, R.C. Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res. 1988, 451, 205–212.
7. Holmstrom, K.M.; Finkel, T. Cellular mechanisms and physiological consequences of redox-dependent signalling. Nat. Rev. Mol. Cell Biol. 2014, 15, 411–421.
8. Kawamata, T.; Akiyama, H.; Yamada, T.; McGeer, P.L. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am. J. Pathol. 1992, 140, 691–707.
9. McGeer, P.L.; Itagaki, S.; Boyes, B.E.; McGeer, E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 1988, 38, 1285–1291.
10. Sapp, E.; Kegel, K.B.; Aronin, N.; Hashikawa, T.; Uchiyama, Y.; Tohyama, K.; Bhide, P.G.; Vonsattel, J.P.; DiFiglia, M. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J. Neuropathol. Exp. Neurol. 2001, 60, 161–172.
11. Ellrichmann, G.; Reick, C.; Saft, C.; Linker, R.A. The role of the immune system in Huntington’s disease. Clin. Dev. Immunol. 2013, doi:10.1155/2013/541259.
12. Hirsch, E.C.; Hunot, S. Neuroinflammation in Parkinson’s disease: A target for neuroprotection? Lancet Neurol. 2009, 8, 382–397.
13. De Felice, F.G.; Velasco, P.T.; Lambert, M.P.; Viola, K.; Fernandez, S.J.; Ferreira, S.T.; Klein, W.L. Aβ oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J. Biol. Chem. 2007, 282, 11590–11601.
14. Mattson, M.P.; Cheng, B.; Davis, D.; Bryant, K.; Lieberburg, I.; Rydel, R.E. β-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci. 1992, 12, 376–389.
15. Wenk, G.L.; Parsons, C.G.; Danysz, W. Potential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: Focus on memantine. Behav. Pharmacol. 2006, 17, 411–424.
16. Wolf, H. The effect of hormones and vitamin B6 on urinary excretion of metabolites of the kynurenine pathway. Scand. J. Clin. Lab. Investig. Suppl. 1974, 136, 1–186.
17. Guillemin, G.J.; Kerr, S.J.; Pemberton, L.A.; Smith, D.G.; Smythe, G.A.; Armati, P.J.; Brew, B.J. IFN-β1b induces kynurenine pathway metabolism in human macrophages: Potential implications for multiple sclerosis treatment. J. Interferon Cytokine Res. 2001, 21, 1097–1101.
18. Pemberton, L.A.; Kerr, S.J.; Smythe, G.; Brew, B.J. Quinolinic acid production by macrophages stimulated with IFN-γ, TNF-α, and IFN-α. J. Interferon Cytokine Res. 1997, 17, 589–595.
19. Heyes, M.P.; Chen, C.Y.; Major, E.O.; Saito, K. Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types. Biochem. J. 1997, 326 Pt 2, 351–356.
20. Connor, T.J.; Starr, N.; O’Sullivan, J.B.; Harkin, A. Induction of indolamine 2,3-dioxygenase and kynurenine 3-monooxygenase in rat brain following a systemic inflammatory challenge: A role for IFN-γ? Neurosci. Lett. 2008, 441, 29–34.
21. Austin, C.J.; Rendina, L.M. Targeting key dioxygenases in tryptophan-kynurenine metabolism for immunomodulation and cancer chemotherapy. Drug Discov. Today 2014, doi:10.1016/j.drudis.2014.11.007.
22. Sedlmayr, P. Indoleamine 2,3-dioxygenase in materno–fetal interaction. Curr. Drug MeTable 2007, 8, 205–208.
23. Reyes Ocampo, J.; Lugo Huitron, R.; Gonzalez-Esquivel, D.; Ugalde-Muniz, P.; Jimenez-Anguiano, A.; Pineda, B.; Pedraza-Chaverri, J.; Rios, C.; Perez de la Cruz, V. Kynurenines with neuroactive and redox properties: Relevance to aging and brain diseases. Oxid. Med. Cell. Longev. 2014, doi:10.1155/2014/646909.
24. Opitz, C.A.; Litzenburger, U.M.; Sahm, F.; Ott, M.; Tritschler, I.; Trump, S.; Schumacher, T.; Jestaedt, L.; Schrenk, D.; Weller, M., et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 2011, 478, 197–203.
25. Denison, M.S.; Rogers, J.M.; Rushing, S.R.; Jones, C.L.; Tetangco, S.C.; Heath-Pagliuso, S. Analysis of the aryl hydrocarbon receptor (AhR) signal transduction pathway. Curr. Protoc. Toxicol. 2002, doi:10.1002/0471140856.tx0408s11.
26. Denison, M.S.; Nagy, S.R. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu. Rev. Pharmacol. Toxicol. 2003, 43, 309–334.
27. Kitamura, M.; Kasai, A. Cigarette smoke as a trigger for the dioxin receptor-mediated signaling pathway. Cancer Lett. 2007, 252, 184–194.
28. Mason, G.G. Dioxin-receptor ligands in urban air and vehicle exhaust. Environ. Health Perspect. 1994, 102 (Suppl. 4), 111–116.
29. Bunger, M.K.; Glover, E.; Moran, S.M.; Walisser, J.A.; Lahvis, G.P.; Hsu, E.L.; Bradfield, C.A. Abnormal liver development and resistance to 2,3,7,8-tetrachlorodibenzo-p-dioxin toxicity in mice carrying a mutation in the DNA-binding domain of the aryl hydrocarbon receptor. Toxicol. Sci. 2008, 106, 83–92.
30. Julliard, W.; Fechner, J.H.; Mezrich, J.D. The aryl hydrocarbon receptor meets immunology: Friend or foe? A little of both. Front. Immunol. 2014, 5, doi:10.3389/fimmu.2014.00458.
31. Vogel, C.F.; Khan, E.M.; Leung, P.S.; Gershwin, M.E.; Chang, W.L.; Wu, D.; Haarmann-Stemmann, T.; Hoffmann, A.; Denison, M.S. Cross-talk between aryl hydrocarbon receptor and the inflammatory response: A role for nuclear factor-κB. J. Biol. Chem. 2014, 289, 1866–1875.
32. Murray, I.A.; Patterson, A.D.; Perdew, G.H. Aryl hydrocarbon receptor ligands in cancer: Friend and foe. Nat. Rev. Cancer 2014, 14, 801–814.
33. DiNatale, B.C.; Murray, I.A.; Schroeder, J.C.; Flaveny, C.A.; Lahoti, T.S.; Laurenzana, E.M.; Omiecinski, C.J.; Perdew, G.H. Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. Toxicol. Sci. 2010, 115, 89–97.
34. Gal, E.M.; Sherman, A.D. Synthesis and metabolism of L-kynurenine in rat brain. J. Neurochem. 1978, 30, 607–613.
35. Moroni, F.; Russi, P.; Lombardi, G.; Beni, M.; Carla, V. Presence of kynurenic acid in the mammalian brain. J. Neurochem. 1988, 51, 177–180.
36. Kessler, M.; Terramani, T.; Lynch, G.; Baudry, M. A glycine site associated with N-methyl-D-aspartic acid receptors: Characterization and identification of a new class of antagonists. J. Neurochem. 1989, 52, 1319–1328.
37. Danysz, W.; Fadda, E.; Wroblewski, J.T.; Costa, E. Kynurenate and 2-amino-5-phosphonovalerate interact with multiple binding sites of the N-methyl-D-aspartate-sensitive glutamate receptor domain. Neurosci. Lett. 1989, 96, 340–344.
38. Perkins, M.N.; Stone, T.W. Actions of kynurenic acid and quinolinic acid in the rat hippocampus in vivo. Exp. Neurol. 1985, 88, 570–579.
39. Prescott, C.; Weeks, A.M.; Staley, K.J.; Partin, K.M. Kynurenic acid has a dual action on AMPA receptor responses. Neurosci. Lett. 2006, 402, 108–112.
40. Rozsa, E.; Robotka, H.; Vecsei, L.; Toldi, J. The Janus-face kynurenic acid. J. Neural Transm. 2008, 115, 1087–1091.
41. Hilmas, C.; Pereira, E.F.; Alkondon, M.; Rassoulpour, A.; Schwarcz, R.; Albuquerque, E.X. The brain metabolite kynurenic acid inhibits α7 nicotinic receptor activity and increases non-α7 nicotinic receptor expression: Physiopathological implications. J. Neurosci. 2001, 21, 7463–7473.
42. Wang, J.; Simonavicius, N.; Wu, X.; Swaminath, G.; Reagan, J.; Tian, H.; Ling, L. Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J. Biol. Chem. 2006, 281, 22021–22028.
43. Alkondon, M.; Pereira, E.F.; Todd, S.W.; Randall, W.R.; Lane, M.; Albuquerque, E.X. Functional G-protein coupled receptor 35 is expressed by neurons in the CA1 field of the hippocampus. Biochem. Pharmacol. 2014, doi:10.1016/j.bcp.2014.12.009.
44. Ohshiro, H.; Tonai-Kachi, H.; Ichikawa, K. GPR35 is a functional receptor in rat dorsal root ganglion neurons. Biochem. Biophys. Res. Commun. 2008, 365, 344–348.
45. Lugo-Huitron, R.; Blanco-Ayala, T.; Ugalde-Muniz, P.; Carrillo-Mora, P.; Pedraza-Chaverri, J.; Silva-Adaya, D.; Maldonado, P.D.; Torres, I.; Pinzon, E.; Ortiz-Islas, E., et al. On the antioxidant properties of kynurenic acid: Free radical scavenging activity and inhibition of oxidative stress. Neurotoxicol. Teratol. 2011, 33, 538–547.
46. Schuck, P.F.; Tonin, A.; da Costa Ferreira, G.; Viegas, C.M.; Latini, A.; Duval Wannmacher, C.M.; de Souza Wyse, A.T.; Dutra-Filho, C.S.; Wajner, M. Kynurenines impair energy metabolism in rat cerebral cortex. Cell. Mol. Neurobiol. 2007, 27, 147–160.
47. Gaubert, S.; Bouchaut, M.; Brumas, V.; Berthon, G. Copper—Ligand interactions and the physiological free radical processes. Part 3. Influence of histidine, salicylic acid and anthranilic acid on copper-driven Fenton chemistry in vitro. Free Radic. Res. 2000, 32, 451–461.
48. Miche, H.; Brumas, V.; Berthon, G. Copper(II) interactions with nonsteroidal antiinflammatory agents. II. Anthranilic acid as a potential. OH-inactivating ligand. J. Inorg. Biochem. 1997, 68, 27–38.
49. Bender, D.A.; McCreanor, G.M. The preferred route of kynurenine metabolism in the rat. Biochim. Biophys. Acta 1982, 717, 56–60.
50. Eastman, C.L.; Guilarte, T.R. The role of hydrogen peroxide in the in vitro cytotoxicity of 3-hydroxykynurenine. Neurochem. Res. 1990, 15, 1101–1107.
51. Ishii, T.; Iwahashi, H.; Sugata, R.; Kido, R. Formation of hydroxanthommatin-derived radical in the oxidation of 3-hydroxykynurenine. Arch. Biochem. Biophys. 1992, 294, 616–622.
52. Okuda, S.; Nishiyama, N.; Saito, H.; Katsuki, H. Hydrogen peroxide-mediated neuronal cell death induced by an endogenous neurotoxin, 3-hydroxykynurenine. Proc. Natl. Acad. Sci. USA 1996, 93, 12553–12558.
53. Vazquez, S.; Garner, B.; Sheil, M.M.; Truscott, R.J. Characterisation of the major autoxidation products of 3-hydroxykynurenine under physiological conditions. Free Radic. Res. 2000, 32, 11–23.
54. Pinelli, A.; Ossi, C.; Colombo, R.; Tofanetti, O.; Spazzi, L. Experimental convulsions in rats induced by intraventricular administration of kynurenine and structurally related compounds. Neuropharmacology 1984, 23, 333–337.
55. Nakagami, Y.; Saito, H.; Katsuki, H. 3-Hydroxykynurenine toxicity on the rat striatum in vivo. Jpn. J. Pharmacol. 1996, 71, 183–186.
56. Mizdrak, J.; Hains, P.G.; Truscott, R.J.; Jamie, J.F.; Davies, M.J. Tryptophan-derived ultraviolet filter compounds covalently bound to lens proteins are photosensitizers of oxidative damage. Free Radic. Biol. Med. 2008, 44, 1108–1119.
57. Leipnitz, G.; Schumacher, C.; Dalcin, K.B.; Scussiato, K.; Solano, A.; Funchal, C.; Dutra-Filho, C.S.; Wyse, A.T.; Wannmacher, C.M.; Latini, A., et al. In vitro evidence for an antioxidant role of 3-hydroxykynurenine and 3-hydroxyanthranilic acid in the brain. Neurochem. Int. 2007, 50, 83–94.
58. Colin-Gonzalez, A.L.; Maldonado, P.D.; Santamaria, A. 3-Hydroxykynurenine: An intriguing molecule exerting dual actions in the central nervous system. Neurotoxicology 2013, 34, 189–204.
59. Dykens, J.A.; Sullivan, S.G.; Stern, A. Oxidative reactivity of the tryptophan metabolites 3-hydroxyanthranilate, cinnabarinate, quinolinate and picolinate. Biochem. Pharmacol. 1987, 36, 211–217.
60. Fazio, F.; Lionetto, L.; Molinaro, G.; Bertrand, H.O.; Acher, F.; Ngomba, R.T.; Notartomaso, S.; Curini, M.; Rosati, O.; Scarselli, P., et al. Cinnabarinic acid, an endogenous metabolite of the kynurenine pathway, activates type 4 metabotropic glutamate receptors. Mol. Pharmacol. 2012, 81, 643–656.
61. Lowe, M.M.; Mold, J.E.; Kanwar, B.; Huang, Y.; Louie, A.; Pollastri, M.P.; Wang, C.; Patel, G.; Franks, D.G.; Schlezinger, J., et al. Identification of cinnabarinic acid as a novel endogenous aryl hydrocarbon receptor ligand that drives IL-22 production. PLoS ONE 2014, 9, e87877.
62. Morita, T.; Saito, K.; Takemura, M.; Maekawa, N.; Fujigaki, S.; Fujii, H.; Wada, H.; Takeuchi, S.; Noma, A.; Seishima, M., et al. 3-Hydroxyanthranilic acid, an L-tryptophan metabolite, induces apoptosis in monocyte-derived cells stimulated by interferon-gamma. Ann. Clin. Biochem. 2001, 38, 242–251.
63. Quagliariello, E.; Papa, S.; Saccone, C.; Alifano, A. Effect of 3-hydroxyanthranilic acid on the mitochondrial respiratory system. Biochem. J. 1964, 91, 137–146.
64. Fallarino, F.; Grohmann, U.; Vacca, C.; Bianchi, R.; Orabona, C.; Spreca, A.; Fioretti, M.C.; Puccetti, P. T cell apoptosis by tryptophan catabolism. Cell Death Differ. 2002, 9, 1069–1077.
65. Christen, S.; Peterhans, E.; Stocker, R. Antioxidant activities of some tryptophan metabolites: Possible implication for inflammatory diseases. Proc. Natl. Acad. Sci. USA 1990, 87, 2506–2510.
66. Murakami, K.; Haneda, M.; Qiao, S.; Naruse, M.; Yoshino, M. Prooxidant action of rosmarinic acid: Transition metal-dependent generation of reactive oxygen species. Toxicol. In Vitro 2007, 21, 613–617.
67. Murakami, K.; Ito, M.; Yoshino, M. Xanthurenic acid inhibits metal ion-induced lipid peroxidation and protects NADP-isocitrate dehydrogenase from oxidative inactivation. J. Nutr. Sci. Vitaminol. (Tokyo) 2001, 47, 306–310.
68. Aggett, P.J.; Fenwick, P.K.; Kirk, H. An in vitro study of the effect of picolinic acid on metal translocation across lipid bilayers. J. Nutr. 1989, 119, 1432–1437.
69. Beskid, M.; Jachimowicz, J.; Taraszewska, A.; Kukulska, D. Histological and ultrastructural changes in the rat brain following systemic administration of picolinic acid. Exp. Toxicol. Pathol. 1995, 47, 25–30.
70. Bosco, M.C.; Rapisarda, A.; Massazza, S.; Melillo, G.; Young, H.; Varesio, L. The tryptophan catabolite picolinic acid selectively induces the chemokines macrophage inflammatory protein-1α and-1β in macrophages. J. Immunol. 2000, 164, 3283–3291.
71. Jhamandas, K.; Boegman, R.J.; Beninger, R.J.; Bialik, M. Quinolinate-induced cortical cholinergic damage: Modulation by tryptophan metabolites. Brain Res. 1990, 529, 185–191.
72. Vrooman, L.; Jhamandas, K.; Boegman, R.J.; Beninger, R.J. Picolinic acid modulates kainic acid-evoked glutamate release from the striatum in vitro. Brain Res. 1993, 627, 193–198.
73. Braidy, N.; Grant, R.; Adams, S.; Brew, B.J.; Guillemin, G.J. Mechanism for quinolinic acid cytotoxicity in human astrocytes and neurons. Neurotox. Res. 2009, 16, 77–86.
74. Stone, T.W.; Perkins, M.N. Quinolinic acid: A potent endogenous excitant at amino acid receptors in CNS. Eur. J. Pharmacol. 1981, 72, 411–412.
75. De Carvalho, L.P.; Bochet, P.; Rossier, J. The endogenous agonist quinolinic acid and the non endogenous homoquinolinic acid discriminate between NMDAR2 receptor subunits. Neurochem. Int. 1996, 28, 445–452.
76. Schwarcz, R.; Kohler, C. Differential vulnerability of central neurons of the rat to quinolinic acid. Neurosci. Lett. 1983, 38, 85–90.
77. Tavares, R.G.; Tasca, C.I.; Santos, C.E.; Alves, L.B.; Porciuncula, L.O.; Emanuelli, T.; Souza, D.O. Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes. Neurochem. Int. 2002, 40, 621–627.
78. Rios, C.; Santamaria, A. Quinolinic acid is a potent lipid peroxidant in rat brain homogenates. Neurochem. Res. 1991, 16, 1139–1143.
79. Goda, K.; Kishimoto, R.; Shimizu, S.; Hamane, Y.; Ueda, M. Quinolinic acid and active oxygens. Possible contribution of active oxygens during cell death in the brain. Adv. Exp. Med. Biol. 1996, 398, 247–254.
80. Stipek, S.; Stastny, F.; Platenik, J.; Crkovska, J.; Zima, T. The effect of quinolinate on rat brain lipid peroxidation is dependent on iron. Neurochem. Int. 1997, 30, 233–237.
81. Chen, Y.; Brew, B.J.; Guillemin, G.J. Characterization of the kynurenine pathway in NSC-34 cell line: Implications for amyotrophic lateral sclerosis. J. Neurochem. 2011, 118, 816–825.
82. Espey, M.G.; Chernyshev, O.N.; Reinhard, J.F., Jr.; Namboodiri, M.A.; Colton, C.A. Activated human microglia produce the excitotoxin quinolinic acid. Neuroreport 1997, 8, 431–434.
83. Guillemin, G.J.; Kerr, S.J.; Smythe, G.A.; Smith, D.G.; Kapoor, V.; Armati, P.J.; Croitoru, J.; Brew, B.J. Kynurenine pathway metabolism in human astrocytes: A paradox for neuronal protection. J. Neurochem. 2001, 78, 842–853.
84. Heyes, M.P.; Achim, C.L.; Wiley, C.A.; Major, E.O.; Saito, K.; Markey, S.P. Human microglia convert l-tryptophan into the neurotoxin quinolinic acid. Biochem. J. 1996, 320 Pt 2, 595–597.
85. Rzeski, W.; Kocki, T.; Dybel, A.; Wejksza, K.; Zdzisinska, B.; Kandefer-Szerszen, M.; Turski, W.A.; Okuno, E.; Albrecht, J. Demonstration of kynurenine aminotransferases I and II and characterization of kynurenic acid synthesis in cultured cerebral cortical neurons. J. Neurosci. Res. 2005, 80, 677–682.
86. Guillemin, G.J.; Cullen, K.M.; Lim, C.K.; Smythe, G.A.; Garner, B.; Kapoor, V.; Takikawa, O.; Brew, B.J. Characterization of the kynurenine pathway in human neurons. J. Neurosci. 2007, 27, 12884–12892.
87. Widner, B.; Leblhuber, F.; Walli, J.; Tilz, G.P.; Demel, U.; Fuchs, D. Tryptophan degradation and immune activation in Alzheimer’s disease. J. Neural Transm. 2000, 107, 343–353.
88. Schwarz, M.J.; Guillemin, G.J.; Teipel, S.J.; Buerger, K.; Hampel, H. Increased 3-hydroxykynurenine serum concentrations differentiate Alzheimer’s disease patients from controls. Eur. Arch. Psychiatry Clin. Neurosci. 2013, 263, 345–352.
89. Guillemin, G.J.; Brew, B.J.; Noonan, C.E.; Takikawa, O.; Cullen, K.M. Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer’s disease hippocampus. Neuropathol. Appl. Neurobiol. 2005, 31, 395–404.
90. Rahman, A.; Ting, K.; Cullen, K.M.; Braidy, N.; Brew, B.J.; Guillemin, G.J. The excitotoxin quinolinic acid induces tau phosphorylation in human neurons. PLoS ONE 2009, 4, e6344.
91. Baran, H.; Jellinger, K.; Deecke, L. Kynurenine metabolism in Alzheimer’s disease. J. Neural Transm. 1999, 106, 165–181.
92. Braak, H.; del Tredici, K.; Rub, U.; de Vos, R.A.; Jansen Steur, E.N.; Braak, E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging 2003, 24, 197–211.
93. Lin, M.T.; Beal, M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443, 787–795.
94. Zadori, D.; Szalardy, L.; Toldi, J.; Fulop, F.; Klivenyi, P.; Vecsei, L. Some molecular mechanisms of dopaminergic and glutamatergic dysfunctioning in Parkinson’s disease. J. Neural Transm. 2013, 120, 673–681.
95. Widner, B.; Leblhuber, F.; Fuchs, D. Increased neopterin production and tryptophan degradation in advanced Parkinson’s disease. J. Neural Transm. 2002, 109, 181–189.
96. Ogawa, T.; Matson, W.R.; Beal, M.F.; Myers, R.H.; Bird, E.D.; Milbury, P.; Saso, S. Kynurenine pathway abnormalities in Parkinson’s disease. Neurology 1992, 42, 1702–1706.
97. Lewitt, P.A.; Li, J.; Lu, M.; Beach, T.G.; Adler, C.H.; Guo, L. 3-hydroxykynurenine and other Parkinson’s disease biomarkers discovered by metabolomic analysis. Mov. Disord. 2013, 28, 1653–1660.
98. Beal, M.F.; Kowall, N.W.; Ellison, D.W.; Mazurek, M.F.; Swartz, K.J.; Martin, J.B. Replication of the neurochemical characteristics of Huntington’s disease by quinolinic acid. Nature 1986, 321, 168–171.
99. Heyes, M.P.; Swartz, K.J.; Markey, S.P.; Beal, M.F. Regional brain and cerebrospinal fluid quinolinic acid concentrations in Huntington’s disease. Neurosci. Lett. 1991, 122, 265–269.
100. Beal, M.F.; Matson, W.R.; Storey, E.; Milbury, P.; Ryan, E.A.; Ogawa, T.; Bird, E.D. Kynurenic acid concentrations are reduced in Huntington’s disease cerebral cortex. J. Neurol. Sci. 1992, 108, 80–87.
101. Beal, M.F.; Matson, W.R.; Swartz, K.J.; Gamache, P.H.; Bird, E.D. Kynurenine pathway measurements in Huntington’s disease striatum: Evidence for reduced formation of kynurenic acid. J. Neurochem. 1990, 55, 1327–1339.
102. Heyes, M.P.; Saito, K.; Crowley, J.S.; Davis, L.E.; Demitrack, M.A.; Der, M.; Dilling, L.A.; Elia, J.; Kruesi, M.J.; Lackner, A., et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 1992, 115 Pt 5, 1249–1273.
103. Jauch, D.; Urbanska, E.M.; Guidetti, P.; Bird, E.D.; Vonsattel, J.P.; Whetsell, W.O., Jr.; Schwarcz, R. Dysfunction of brain kynurenic acid metabolism in Huntington’s disease: Focus on kynurenine aminotransferases. J. Neurol. Sci. 1995, 130, 39–47.
104. Pearson, S.J.; Reynolds, G.P. Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington’s disease. Neurosci. Lett. 1992, 144, 199–201.
105. Guidetti, P.; Luthi-Carter, R.E.; Augood, S.J.; Schwarcz, R. Neostriatal and cortical quinolinate levels are increased in early grade Huntington’s disease. Neurobiol. Dis. 2004, 17, 455–461.
106. Rosen, D.R. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 364, 362.
107. Chen, Y.; Stankovic, R.; Cullen, K.M.; Meininger, V.; Garner, B.; Coggan, S.; Grant, R.; Brew, B.J.; Guillemin, G.J. The kynurenine pathway and inflammation in amyotrophic lateral sclerosis. Neurotox. Res. 2010, 18, 132–142.
108. Ilzecka, J.; Kocki, T.; Stelmasiak, Z.; Turski, W.A. Endogenous protectant kynurenic acid in amyotrophic lateral sclerosis. Acta Neurol. Scand. 2003, 107, 412–418.
109. Monaco, F.; Fumero, S.; Mondino, A.; Mutani, R. Plasma and cerebrospinal fluid tryptophan in multiple sclerosis and degenerative diseases. J. Neurol. Neurosurg. Psychiatry 1979, 42, 640–641.
110. Ott, M.; Demisch, L.; Engelhardt, W.; Fischer, P.A. Interleukin-2, soluble interleukin-2-receptor, neopterin, L-tryptophan and β2-microglobulin levels in CSF and serum of patients with relapsing-remitting or chronic-progressive multiple sclerosis. J. Neurol. 1993, 241, 108–114.
111. Hartai, Z.; Klivenyi, P.; Janaky, T.; Penke, B.; Dux, L.; Vecsei, L. Kynurenine metabolism in multiple sclerosis. Acta Neurol. Scand. 2005, 112, 93–96.
112. Rejdak, K.; Bartosik-Psujek, H.; Dobosz, B.; Kocki, T.; Grieb, P.; Giovannoni, G.; Turski, W.A.; Stelmasiak, Z. Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients. Neurosci. Lett. 2002, 331, 63–65.
113. Rejdak, K.; Petzold, A.; Kocki, T.; Kurzepa, J.; Grieb, P.; Turski, W.A.; Stelmasiak, Z. Astrocytic activation in relation to inflammatory markers during clinical exacerbation of relapsing-remitting multiple sclerosis. J. Neural Transm. 2007, 114, 1011–1015.
114. Amirkhani, A.; Rajda, C.; Arvidsson, B.; Bencsik, K.; Boda, K.; Seres, E.; Markides, K.E.; Vecsei, L.; Bergquist, J. Interferon-β affects the tryptophan metabolism in multiple sclerosis patients. Eur. J. Neurol. 2005, 12, 625–631.
115. Durastanti, V.; Lugaresi, A.; Bramanti, P.; Amato, M.; Bellantonio, P.; de Luca, G.; Picconi, O.; Fantozzi, R.; Locatelli, L.; Solda, A., et al. Neopterin production and tryptophan degradation during 24-months therapy with interferon β-1a in multiple sclerosis patients. J. Transl. Med. 2011, 9, doi:10.1186/1479-5876-9-42.
116. Mandi, Y.; Vecsei, L. The kynurenine system and immunoregulation. J. Neural Transm. 2012, 119, 197–209.
117. Heaton, R.K.; Clifford, D.B.; Franklin, D.R., Jr.; Woods, S.P.; Ake, C.; Vaida, F.; Ellis, R.J.; Letendre, S.L.; Marcotte, T.D.; Atkinson, J.H., et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: Charter Study. Neurology 2010, 75, 2087–2096.
118. Heyes, M.P.; Brew, B.J.; Martin, A.; Price, R.W.; Salazar, A.M.; Sidtis, J.J.; Yergey, J.A.; Mouradian, M.M.; Sadler, A.E.; Keilp, J., et al. Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: Relationship to clinical and neurological status. Ann. Neurol. 1991, 29, 202–209.
119. Guillemin, G.J.; Kerr, S.J.; Brew, B.J. Involvement of quinolinic acid in AIDS dementia complex. Neurotox. Res. 2005, 7, 103–123.
120. Chiarugi, A.; Carpenedo, R.; Molina, M.T.; Mattoli, L.; Pellicciari, R.; Moroni, F. Comparison of the neurochemical and behavioral effects resulting from the inhibition of kynurenine hydroxylase and/or kynureninase. J. Neurochem. 1995, 65, 1176–1183.
121. Colabroy, K.L.; Zhai, H.; Li, T.; Ge, Y.; Zhang, Y.; Liu, A.; Ealick, S.E.; McLafferty, F.W.; Begley, T.P. The mechanism of inactivation of 3-hydroxyanthranilate-3,4-dioxygenase by 4-chloro-3-hydroxyanthranilate. Biochemistry 2005, 44, 7623–7631.
122. Walsh, H.A.; O’Shea, K.C.; Botting, N.P. Comparative inhibition by substrate analogues 3-methoxy-and 3-hydroxydesaminokynurenine and an improved 3 step purification of recombinant human kynureninase. BMC Biochem. 2003, 4, doi:10.1186/1471-2091-4-13.
123. Amori, L.; Guidetti, P.; Pellicciari, R.; Kajii, Y.; Schwarcz, R. On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo. J. Neurochem. 2009, 109, 316–325.
124. Gregoire, L.; Rassoulpour, A.; Guidetti, P.; Samadi, P.; Bedard, P.J.; Izzo, E.; Schwarcz, R.; di Paolo, T. Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys. Behav. Brain Res. 2008, 186, 161–167.
125. Samadi, P.; Gregoire, L.; Rassoulpour, A.; Guidetti, P.; Izzo, E.; Schwarcz, R.; Bedard, P.J. Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in Parkinsonian monkeys. Mov. Disord. 2005, 20, 792–802.
126. Zwilling, D.; Huang, S.Y.; Sathyasaikumar, K.V.; Notarangelo, F.M.; Guidetti, P.; Wu, H.Q.; Lee, J.; Truong, J.; Andrews-Zwilling, Y.; Hsieh, E.W., et al. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 2011, 145, 863–874.
127. Beconi, M.G.; Yates, D.; Lyons, K.; Matthews, K.; Clifton, S.; Mead, T.; Prime, M.; Winkler, D.; O’Connell, C.; Walter, D., et al. Metabolism and pharmacokinetics of JM6 in mice: JM6 is not a prodrug for Ro-61-8048. Drug Metab. Dispos. 2012, 40, 2297–2306.
128. Chauvel, V.; Vamos, E.; Pardutz, A.; Vecsei, L.; Schoenen, J.; Multon, S. Effect of systemic kynurenine on cortical spreading depression and its modulation by sex hormones in rat. Exp. Neurol. 2012, 236, 207–214.
129. Silva-Adaya, D.; Perez-de la Cruz, V.; Villeda-Hernandez, J.; Carrillo-Mora, P.; Gonzalez-Herrera, I.G.; Garcia, E.; Colin-Barenque, L.; Pedraza-Chaverri, J.; Santamaria, A. Protective effect of L-kynurenine and probenecid on 6-hydroxydopamine-induced striatal toxicity in rats: Implications of modulating kynurenate as a protective strategy. Neurotoxicol. Teratol. 2011, 33, 303–312.
130. Carrillo-Mora, P.; Mendez-Cuesta, L.A.; Perez-de la Cruz, V.; Fortoul-van der Goes, T.I.; Santamaria, A. Protective effect of systemic L-kynurenine and probenecid administration on behavioural and morphological alterations induced by toxic soluble amyloid β(25–35) in rat hippocampus. Behav. Brain Res. 2010, 210, 240–250.
131. Robotka, H.; Sas, K.; Agoston, M.; Rozsa, E.; Szenasi, G.; Gigler, G.; Vecsei, L.; Toldi, J. Neuroprotection achieved in the ischaemic rat cortex with L-kynurenine sulphate. Life Sci. 2008, 82, 915–919.
132. Sas, K.; Robotka, H.; Rozsa, E.; Agoston, M.; Szenasi, G.; Gigler, G.; Marosi, M.; Kis, Z.; Farkas, T.; Vecsei, L., et al. Kynurenine diminishes the ischemia-induced histological and electrophysiological deficits in the rat hippocampus. Neurobiol. Dis. 2008, 32, 302–308.
133. Miranda, A.F.; Sutton, M.A.; Beninger, R.J.; Jhamandas, K.; Boegman, R.J. Quinolinic acid lesion of the nigrostriatal pathway: Effect on turning behaviour and protection by elevation of endogenous kynurenic acid in Rattus norvegicus. Neurosci. Lett. 1999, 262, 81–84.
134. Marosi, M.; Nagy, D.; Farkas, T.; Kis, Z.; Rozsa, E.; Robotka, H.; Fulop, F.; Vecsei, L.; Toldi, J. A novel kynurenic acid analogue: A comparison with kynurenic acid. An in vitro electrophysiological study. J. Neural Transm. 2010, 117, 183–188.
135. Zadori, D.; Nyiri, G.; Szonyi, A.; Szatmari, I.; Fulop, F.; Toldi, J.; Freund, T.F.; Vecsei, L.; Klivenyi, P. Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington’s disease. J. Neural Transm. 2011, 118, 865–875.
136. Tiszlavicz, Z.; Nemeth, B.; Fulop, F.; Vecsei, L.; Tapai, K.; Ocsovszky, I.; Mandi, Y. Different inhibitory effects of kynurenic acid and a novel kynurenic acid analogue on tumour necrosis factor-alpha (TNF-α) production by mononuclear cells, HMGB1 production by monocytes and HNP1-3 secretion by neutrophils. Naunyn-Schmiedeberg’s Arch. Pharmacol. 2011, 383, 447–455.
137. Gellert, L.; Fuzik, J.; Goblos, A.; Sarkozi, K.; Marosi, M.; Kis, Z.; Farkas, T.; Szatmari, I.; Fulop, F.; Vecsei, L., et al. Neuroprotection with a new kynurenic acid analog in the four-vessel occlusion model of ischemia. Eur. J. Pharmacol. 2011, 667, 182–187.
138. Gellert, L.; Varga, D.; Ruszka, M.; Toldi, J.; Farkas, T.; Szatmari, I.; Fulop, F.; Vecsei, L.; Kis, Z. Behavioural studies with a newly developed neuroprotective KYNA-amide. J. Neural Transm. 2012, 119, 165–172.
139. Fulop, F.; Szatmari, I.; Vamos, E.; Zadori, D.; Toldi, J.; Vecsei, L. Syntheses, transformations and pharmaceutical applications of kynurenic acid derivatives. Curr. Med. Chem. 2009, 16, 4828–4842.
140. Fulop, F.; Szatmari, I.; Toldi, J.; Vecsei, L. Modifications on the carboxylic function of kynurenic acid. J. Neural Transm. 2012, 119, 109–114.
141. Kemp, J.A.; Foster, A.C.; Leeson, P.D.; Priestley, T.; Tridgett, R.; Iversen, L.L.; Woodruff, G.N. 7-Chlorokynurenic acid is a selective antagonist at the glycine modulatory site of the N-methyl-D-aspartate receptor complex. Proc. Natl. Acad. Sci. USA 1988, 85, 6547–6550.
142. Domenici, M.R.; Longo, R.; Sagratella, S. 7-Chlorokynurenic acid prevents in vitro epileptiform and neurotoxic effects due to kainic acid. Gen. Pharmacol. 1996, 27, 113–116.
143. Wu, H.Q.; Lee, S.C.; Schwarcz, R. Systemic administration of 4-chlorokynurenine prevents quinolinate neurotoxicity in the rat hippocampus. Eur. J. Pharmacol. 2000, 390, 267–274.